
ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and …

Janssen has formalised its collaboration with ViiV Healthcare on the Phase III development and commercialisation of a two-drug regimen to …

Leading UK-based HIV and sexual health charity The Terrence Higgins Trust has announced the appointment of Ian Green as the …

Specialist HIV company ViiV Healthcare has agreed deals worth up to $1.46 billion to purchase Bristol-Myers Squibb’s late stage HIV …

Johnson &Johnson is entering four new public-private partnerships aimed at significantly reducing the burden of HIV incidence among young girls …

The Medicines Patent Pool (MPP) and the University of Liverpool have agreed a partnership to use the university’s solid drug …

Gilead Sciences has won marketing authorisation from the European Commission (EC) for the once-daily single tablet regimen Genvoya as an …

The European Commission has kicked-off a new €23 million research program to bring together researchers to work on a potential …

Gilead Sciences has today announced 96-week results from two Phase III studies evaluating its investigational once-daily single tablet regimen (STR), …

The United Nations AIDS agency, UNAIDS, has called on governments and the pharmaceutical industry to ensure that medicines remain accessible …

Switching patients to Triumeq, a once-daily combination treatment for HIV, is as effective as remaining on antiretroviral therapy in certain …

UK researchers say Truvada, Gilead’s HIV prevention treatment, should be added to the country’s ‘HIV prevention toolkit’, after a study …

GlaxoSmithKline is boosting its philanthropic efforts in R&D into HIV/AIDS by teaming up with academic researchers to launch a new …

Since being spun-off from GSK and Pfizer, specialist HIV firm ViiV Healthcare has earned the best corporate reputation amongst patients …

GlaxoSmithKline’s pharma sales continued to slide in the first quarter of 2015, but ViiV healthcare and the portfolios acquired from …